Comparison of conduits for leg revascularization

Area of Science:

• Vascular Surgery
• Biomaterials Science
• Clinical Outcomes Research

Background:

• The saphenous vein (SV) is the preferred autologous conduit for lower limb revascularization.
• Alternative synthetic or processed biological grafts, including human umbilical vein (HUV) and polytetrafluoroethylene (PTFE), are used when SV is unavailable.
• Comparative long-term patency data for these conduits in lower limb revascularization are crucial for clinical decision-making.

Purpose of the Study:

• To compare the 3-year graft patency rates of saphenous vein (SV), human umbilical vein (HUV), and polytetrafluoroethylene (PTFE) conduits in lower limb revascularization.
• To identify factors influencing graft patency and assess their impact on conduit performance.
• To evaluate the risk-adjusted outcomes for each conduit type.

Main Methods:

• Retrospective analysis of 218 patients undergoing lower limb revascularization using SV, HUV, or PTFE grafts.
• Assessment of 3-year graft patency rates.
• Development of a risk score based on surgical indication, distal anastomosis site, and angiographic runoff to stratify patient risk.

Main Results:

• Overall 3-year patency: SV (75%) significantly outperformed HUV (34%) and PTFE (33%).
• Factors influencing patency included surgical indication, distal anastomosis site, and angiographic runoff.
• SV demonstrated superior patency across all risk subgroups, with risk scores ranging from low (3-4) to high (7-9). HUV and PTFE showed equivalent patency, particularly in higher-risk patients.

Conclusions:

• Saphenous vein grafts remain the conduit of choice for lower limb revascularization due to superior long-term patency.
• Human umbilical vein and polytetrafluoroethylene grafts offer equivalent and acceptable patency rates when SV is not a viable option.
• Risk stratification is important for predicting outcomes, but SV consistently provides better results regardless of risk level.